Adjuvanted influenza vaccine
Sponsors
GlaxoSmithKline, Novartis Vaccines, Novartis, Marshfield Clinic Research Foundation
Conditions
Immune ResponseInfluenzaInfluenza DiseaseInfluenza Infection
Phase 1
Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine
CompletedNCT00559975
Start: 2007-10-31End: 2008-05-31Target: 60Updated: 2009-11-05
Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines
CompletedNCT00735020
Start: 2008-06-30End: 2008-08-31Updated: 2014-01-24
Phase 2
Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population
CompletedNCT00377585
Start: 2006-09-22End: 2007-01-30Target: 3350Updated: 2017-04-24
Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Adults
CompletedNCT00386698
Start: 2006-10-31End: 2006-12-31Updated: 2016-10-07
Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases.
CompletedNCT00522067
Start: 2007-06-30End: 2007-07-31Updated: 2016-12-01